- Home
- DTM vs MRNA Comparison
DTM vs MRNA Comparison
Compare DTM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTM
- MRNA
- Stock Information
- Founded
- DTM 2021
- MRNA 2010
- Country
- DTM United States
- MRNA United States
- Employees
- DTM N/A
- MRNA N/A
- Industry
- DTM Oil & Gas Production
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTM Utilities
- MRNA Health Care
- Exchange
- DTM Nasdaq
- MRNA Nasdaq
- Market Cap
- DTM 10.6B
- MRNA 10.9B
- IPO Year
- DTM N/A
- MRNA 2018
- Fundamental
- Price
- DTM $104.61
- MRNA $24.05
- Analyst Decision
- DTM Buy
- MRNA Hold
- Analyst Count
- DTM 12
- MRNA 19
- Target Price
- DTM $109.17
- MRNA $43.50
- AVG Volume (30 Days)
- DTM 719.2K
- MRNA 9.3M
- Earning Date
- DTM 10-28-2025
- MRNA 08-01-2025
- Dividend Yield
- DTM 3.14%
- MRNA N/A
- EPS Growth
- DTM N/A
- MRNA N/A
- EPS
- DTM 3.74
- MRNA N/A
- Revenue
- DTM $1,109,000,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- DTM $26.61
- MRNA N/A
- Revenue Next Year
- DTM $8.37
- MRNA $10.17
- P/E Ratio
- DTM $27.93
- MRNA N/A
- Revenue Growth
- DTM 15.28
- MRNA N/A
- 52 Week Low
- DTM $73.52
- MRNA $23.15
- 52 Week High
- DTM $114.50
- MRNA $79.96
- Technical
- Relative Strength Index (RSI)
- DTM 56.29
- MRNA 33.68
- Support Level
- DTM $101.72
- MRNA $23.40
- Resistance Level
- DTM $104.69
- MRNA $25.64
- Average True Range (ATR)
- DTM 2.00
- MRNA 1.08
- MACD
- DTM 0.22
- MRNA -0.18
- Stochastic Oscillator
- DTM 73.55
- MRNA 12.52
About DTM DT Midstream Inc.
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.